Opinion · 29 Oct 2025
Case reportPublished 26 Apr 2023
An Analysis Using Propensity Scores Reveals that Monitoring High-Risk Individuals for Pancreatic Cancer Results in Better Outcomes
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background & Aims: Improved outcomes have been reported by recent high-risk pancreatic cancer surveillance programs. This study looked at whether patients with a CDKN2A/p16 pathogenic variant diagnosed under surveillance had better outcomes for pancreatic ductal adenocarcinoma (PDAC) than those with PDAC diagnosed outside of surveillance. Method: We compared resectability, stage, and survival in a propensity score-matched cohort using data from the Netherlands Cancer Registry between PDAC patients diagnosed under surveillance and non-surveillance patients. Endurance examinations were adapted to likely impacts of lead time. Results: The Netherlands Cancer Registry identified 43,762 PDAC patients between January 2000 and December 2020. Based on age at diagnosis, sex, year of diagnosis, and tumor location, 151 non-surveillance patients and 31 patients with PDAC under surveillance were matched 1:15. 5.8% of patients outside of surveillance had stage I cancer, whereas 38.7% of surveillance patients had PDAC (odds ratio [OR], 0.09; (0.04–0.19), 95 percent confidence interval (CI). Overall, a surgical resection was performed on 18.7% of non-surveillance patients versus 71% of surveillance patients (OR, 10.62; 95% CI, 4.56–26.63). With a 5-year survival rate of 32.4% and a median overall survival of 26.8 months, patients on surveillance had a better prognosis than non-surveillance patients, who had a 5-year survival rate of 4.3% and a median overall survival of 5.2 months (hazard ratio, 0.31; 95% CI 0.19–0.50). Surveillance patients had significantly longer survival rates than non-surveillance patients for all adjusted lead times. Conclusion: Compared to patients with PDAC who are not monitored, those with PDAC who are carriers of a CDKN2A/p16 pathogenic variant experience improved survival, earlier detection, and increased respectability.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in International Journal of Inflammation, Cancer and Integrative Therapy.
Short communication · 29 Oct 2025
Systems Biology: From Description to Prediction and Engineering
Editorial · 29 Oct 2025
Cancer Cachexia: Management, Mechanisms, and Future Directions
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Inflammation, Cancer and Integrative Therapy
- SubjectImmunology & Microbiology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Dark Clatte”